Index - Nostopharma

Accelerating New Path

Precision Medicine for Faster Healing

Nostopharma is a women-owned company, specializing in transforming care for bone and connective tissue disorders with precision deliveries. We are developing novel therapies for patients with bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.

2+

Active Programs

3 Pre-clinical Assets

2 Patents Issued

Breakthrough

Our innovative designs provide superior delivery, reduce side effects and costs while they advance human health

At Nostopharma, we are charting a path to transform care for bone and soft tissue disorders as we believe in the power of science to transform lives. Our commitment to quality, innovation, and reliability drives everything we do.

Targeted nanodelivery technology

Advanced molecular intervention

Unlocking the potential of existing drugs

View pipeline

Innovative

Bringing precision to those suffering from bone and soft tissue disorders

Our innovative designs provide superior delivery, so clinicians can achieve greater outcomes, save time, and reduce costs while they advance human health.

What is HO (Heterotopic ossification)?

Heterotopic ossification (HO) is when soft tissues like muscles, tendons, skin and ligaments transform into bone outside the skeleton. Mesenchymal stem cells (MCS) are main cause of HO, as they differentiate into bone cells under certain triggers.

Hedgehog pathway (Hh) inhibitors

Are being developed at Nostopharma for disorders characterized by heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation outside of its normal location

Pipeline

Nostopharma is repurposing already existing Hh inhibitors, previously tested and approved in clinical trials for cancer and inflammatory diseases. Our studies in mouse models of non-hereditary HO have shown that blocking the Hh signaling can significantly inhibit the formation of HO.

← Slide left

Precision therapeutic approach

Targeted interventions minimize systemic side effects and accelerate patient recovery

Molecular targeting

Our treatment acts on the Hh pathway, directly related to MCS differentiation into bone cells

Clinical potential

Nostopharma is repurposing already existing Hh inhibitors, previously tested and approved in clinical trials for cancer and inflammatory diseases with known toxicity and PK profiles

Patient outcomes

Innovative approach promises improved healing and reduced complications

Advancing medical solutions for bone and soft tissue disorders together

Join our mission to transform bone healing through cutting-edge molecular interventions

Collaborate